Overview

Open-Label Lesinurad Monotherapy Extension Study in Gout

Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This study will assess the serum uric acid lowering effects and safety of lesinurad over a long-term timeframe.
Phase:
Phase 3
Details
Lead Sponsor:
Ardea Biosciences, Inc.
Treatments:
Lesinurad